Evan David Seigerman
Stock Analyst at BMO Capital
(3.62)
# 786
Out of 5,154 analysts
55
Total ratings
56.25%
Success rate
5.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $120 → $100 | $61.18 | +63.45% | 2 | Feb 17, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $115.79 | +12.27% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $759.86 | +11.86% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $369.53 | +0.67% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $38.58 | +19.23% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $8.07 | +36.31% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $230.11 | +4.30% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $22.17 | +17.28% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.16 | +26.35% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $13.60 | -26.47% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $57.73 | +73.22% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $27.05 | +33.09% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $4.94 | -39.27% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $990.33 | -60.01% | 1 | Sep 6, 2022 |
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120 → $100
Current: $61.18
Upside: +63.45%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $115.79
Upside: +12.27%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $759.86
Upside: +11.86%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $369.53
Upside: +0.67%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $38.58
Upside: +19.23%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $8.07
Upside: +36.31%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $230.11
Upside: +4.30%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $22.17
Upside: +17.28%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.16
Upside: +26.35%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $13.60
Upside: -26.47%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $57.73
Upside: +73.22%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $27.05
Upside: +33.09%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $4.94
Upside: -39.27%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $990.33
Upside: -60.01%